Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy

Cheng, Xiaoyun; Yang, Guoliang; Schmeler, Katheleen M.; Coleman, Robert L.; Tu, Xiaoyu; Liu, J.; Kavanagh, John J.

doi:10.1016/j.ygyno.2010.12.360

Cited by 91 publications

(71 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31,39 WT1 is an attractive target given that is highly immunogenic and restricted to tumor cells. 39 It is reported that 47-93% of endometrial stromal sarcoma overexpress WT1, underscoring the potential therapeutic role. 31 Targeting WT1 may have potential therapeutic value in the future treatment of endometrial stromal sarcoma.…”

Section: Resultsmentioning

confidence: 99%

Endometrial Stromal Sarcoma

Rauh‐Hain

Carmen

2013

Obstetrics & Gynecology

124

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Endometrial Stromal Sarcoma

Rauh‐Hain

Carmen

2013

Obstetrics & Gynecology

124

View full text Add to dashboard Cite

show abstract

“…There are few studies on the expression of VEGF in uterine sarcoma. In one such report, VEGF was found to be expressed in 54% of ESSs [25] . In our current study, VEGF showed strong expression in a high proportion of the UES tumors, and we predict that therapeutic agents targeting this biomarker could be promising new treatment modalities for UES.…”

Section: Discussionmentioning

confidence: 95%

Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma

Baek

Rhim²,

Kim³

et al. 2017

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: Undifferentiated endometrial sarcoma (UES) is a very rare subtype of uterine sarcoma, which has no consensus on the treatment. We investigated the expression of potential new therapeutic targets in UES to improve its aggressive clinical course and poor survival outcome. Methods: The immunohistochemical expressions of vascular endothelial growth factor (VEGF), c-KIT, c-ABL, platelet derived growth factor receptor (PDGFR), protein kinase B (AKT1), mammalian target of rapamycin, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER2), Wilms tumor (WT1), aromatase inhibitor (CYP19A1), and histone deacetylase (HDAC) series in 10 UES patients were assessed using tissue microarrays. Results: Strongly positive immunoreactivities were observed for VEGF, AKT1, and HDAC2/7 in 8 (80.0%) tumors; for CYP19A1 and HDAC6 in 9 (90%) tumors; and for HDAC1/4/8 in 10 (100%) tumors. Strong expression of CYP19A1 and HDAC6 was associated with distant recurrence (p = 0.030, both), and expression of WT1 indicated a more advanced stage (p = 0.033). UES treated with adjuvant therapy showed better disease-free and overall survivals (both 0 vs. 33.3%, p = 0.003). Conclusion: VEGF, AKT1, CYP19A1, and the HDAC1/2/4/6/7/8 series show an especially high frequency of strong immunoreactivity in UES and can be considered potential therapeutic targets.

show abstract

“…However, spine and hematologic recurrences have also been described in the literature. [16][17][18][19] ESS has shown overall survival rates of 65% at five years but of 32% in those with extrauterine disease. 20 In conclusion, although extremely rare, the diagnosis of ESS presenting as a Bartholin gland cyst should be kept in mind especially in patients between the ages of 40-50 presenting with symptoms of menorrhagia, dysmenorrhea, and pelvic pain or pressure.…”

Section: Discussionmentioning

confidence: 99%

Vulvar extrauterine endometrial stromal sarcoma

Zaza

Arafah

Al-Badawi

2015

Hematology/Oncology and Stem Cell Therapy

View full text Add to dashboard Cite

Endometrial stromal sarcoma (ESS) is an extremely rare neoplasm accounting for only 0.2% of all uterine malignancies and for 15-26% of primary uterine sarcomas. The annual incidence of ESS is 1-2 per million women. Herein, to the best of our knowledge, we present the first reported case of ESS of the vulva in a 50-year-old female presenting with per vaginal spotting over a period of three months. Her past surgical history included a subtotal hysterectomy and left salpingo-oophorectomy for uterine fibroids ten years previously. On examination, a 3.5×3×2 cm cystic mass was found in the right labia majora. The mass was excised and the diagnosis of endometrial stromal sarcoma was made. Subsequent metastatic workup was negative and the patient was started on megestrol acetate. She has remained disease free with no signs or symptoms of recurrent or advanced disease for 28 months.

show abstract

Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy

Cited by 91 publications

References 29 publications

Endometrial Stromal Sarcoma

Endometrial Stromal Sarcoma

Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma

Vulvar extrauterine endometrial stromal sarcoma

Contact Info

Product

Resources

About